FRANKLIN LAKES, N.J., Oct. 22, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Patrick Kaltenbach as executive vice president and chief technology officer, and the promotion of Dave Hickey to executive vice president and president, Life Sciences segment, both effective January 1, 2021.... Read more
FRANKLIN LAKES, N.J., Oct. 5, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD FACSLyric™ Flow Cytometer with the Integrated BD FACSDuet™ Sample Preparation System. The new integrated system enables clinical laboratories to fully automate... Read more
FRANKLIN LAKES, N.J., Aug. 6, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.855 billion for the third fiscal quarter ended June 30, 2020. This represents a decrease of 11.4 percent as reported from the prior-year period, or 9.4 percent on a currency-neutral basis. ... Read more
FRANKLIN LAKES, N.J., July 21, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced additional pandemic orders for needles and syringes from the United States and Canada totaling 177 million injection devices. The new U.S. order for 140 million injection devices brings total U.S. orders from BD... Read more
FRANKLIN LAKES, N.J., July 8, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response,... Read more
FRANKLIN LAKES, N.J., May 7, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.253 billion for the second fiscal quarter ended March 31, 2020. This represents an increase of 1.4 percent as reported over the prior-year period, or 2.4 percent on a currency-neutral... Read more
New Test Uses BD MAX™ System to Augment Supply from Existing Collaborations; Test Results in Under Three HoursApr 13, 2020 FRANKLIN LAKES, N.J., April 13, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA)... Read more
Point-of-care blood test detects evidence of present or past exposure in 15 minutesMar 31, 2020 FRANKLIN LAKES, N.J. MORRISVILLE, N.C., March 31, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioMedomics, a privately held, North Carolina-based clinical diagnostics company, today announced the release of a new point-of-care... Read more
New Diagnostics Have Potential to Increase Capacity of COVID-19 Testing in U.S. by Thousands of Tests Per DayMar 16, 2020 FRANKLIN LAKES, N.J. and BIRMINGHAM, Ala. March 16, 2020 /PRNewswire/ — BD (Becton,Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioGX Inc, a molecular diagnostics company, today announced that the companies have... Read more
BD Kiestra™ IdentifA system is available in Europe (CE marked) and CanadaNov 18, 2019 FRANKLIN LAKES, NJ (November 18, 2019) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced availability in Europe (CE marked) and Canada for the BD Kiestra™ IdentifA system. The new solution helps bring accuracy and efficiency to... Read more